FINALY Good news for all in Sweden! And i am really happy for this news! Hope is here!

The drugs Epclusa, Harvoni, Maviret, Sovaldi, Vosevi and Zepatier are subsidized to patients with hepatitis C, regardless of fibrostatic disease.

TLV(dental and drug organisation) in Sweden has taken new subsidy decisions for all nine drugs against hepatitis C, which have previously been included in the drug benefits. In addition, a decision has been made for a new hepatitis C drug, Vosevi. Six of these ten drugs are now granted subsidies for the treatment of patients in all fibrostatic stages. The other four, Daklinza, Exviera, Olysio and Viekirax, remain in the drug benefits, with the exception of being subsidized only on the other hand for the most severely ill, that is, in cases where the drugs with subsidy in all fibrous states are not appropriate.

The decisions apply as of January 1, 2018 and apply until further notice. In conjunction with the new decisions and the new cost situation, the county council’s new therapies council, the NT council, will update the recommendation for drug selection in the treatment of hepatitis C.

TLV, county councils and companies have had tripartite discussions in connection with price cuts from county councils and new applications for Vosevi. Within the framework of these deliberations, county councils and certain companies have agreed to subscribe to new side agreements which mean that county councils and companies share the risks of treatment length and number of patients. In cases where county councils and companies have signed side agreements, these are part of the basis for TLV’s decisions. The side agreements apply from 1 January 2018 to 31 December 2019.
Background

Hepatitis C is a common disease where a virus infects the liver and damages the liver cells. Most people with hepatitis C live for many years without symptoms, but after time patients can develop cirrhosis and liver cancer and some may need liver transplant to survive.

In 2014, the pharmaceutical market received a major breakthrough with the launch of the new cure medicines against hepatitis C. At the same time, the price was high and the number of patients was high, approximately 40,000 in Sweden. This meant that initially, the drugs against hepatitis C were only subsidized to the most severely ill patients with severe hepatic impairment in fibrostatic stages F3 and F4. In July 2015, the subsidy was extended to include patients with moderate hepatic impairment, fibrous stage F2.

Published December 14, 2017

Updated December 15, 2017

Translated by g from this Source page: https://www.tlv.se/beslut/beslut-lakemedel/begransad-subvention/Lakemedel-mot-hepatit-C-subventioneras-till-samtliga-patienter-oavsett-fibrosstadium/

Best regards to you all /Linus